AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CLARITY PHARMACEUTICALS LTD

2.480

-0.140-5.34%

Volume:2.46M

Turnover:6.11M

Market Cap:922.63M

PE:-8.79

High:2.600

Open:2.580

Low:2.440

Close:2.620

52wk High:5.870

52wk Low:1.800

Shares:372.03M

Float Shares:274.26M

Volume Ratio:1.43

T/O Rate:0.90%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.282

EPS(LYR):-0.201

ROE:-53.45%

ROA:-30.54%

PB:3.96

PE(LYR):-12.31

Loading ...

Overview Company News Filings

Clarity Pharmaceuticals - Reports Two Additional Complete Responses in Secure Trial at 8 Gbq Dose

THOMSON REUTERS

Clarity Pharmaceuticals - 74% Achieve Psa25, 63% Psa50, 53% Psa75, 26% Psa90 in Secure Trial at 8 Gbq

THOMSON REUTERS

Clarity Pharmaceuticals - Most Adverse Events at 8 Gbq Dose were Mild or Moderate and Transient

THOMSON REUTERS

Clarity Pharmaceuticals - 81% Achieve Disease Control, 31% Complete Response/Undetectable Disease at 8 Gbq Dose

THOMSON REUTERS

Clarity Pharmaceuticals Reports Two Additional Complete Responses in SECuRE Trial 8 GBq 67Cu-SAR-bisPSMA Cohort

Clarity Pharmaceuticals Says Two New Participants in Prostate Cancer Trial Achieve Complete Response; Shares Jump 14%

MT Newswires Live

ASX Penny Stocks Spotlight Clarity Pharmaceuticals And 2 More Compelling Picks

Simply Wall St.

Clarity Plans Phase Three Registrational Study of Neuroendocrine Tumor Treatment Candidate; Shares Jump 12%

MT Newswires Live

Clarity Pharmaceuticals Ltd-allison Rossiter Joins Clarity Board of Directors

THOMSON REUTERS

Stock Track | Clarity Pharmaceuticals Soars 5.00% Intraday on R&D Tax Refund and New Manufacturing Agreement

Is Clarity Pharmaceuticals’ (ASX:CU6) Copper Theranostics Pipeline Redefining Its Long-Term Oncology Strategy?

Simply Wall St.

ASX Growth Stocks With High Insider Ownership To Watch

Simply Wall St.

ASX Growth Companies With High Insider Ownership

Simply Wall St.

ASX Growth Leaders With Insider Stakes May 2026

Simply Wall St.

ASX Growth Companies With Significant Insider Ownership

Simply Wall St.

Clarity Pharmaceuticals to Start Registrational Phase 3 Trial in Neuroendocrine Tumors After US FDA Meeting

MT Newswires Live

Trade Alert: CEO, MD & Executive Director Of Clarity Pharmaceuticals Michelle Parker Has Sold Stock

Simply Wall St.

Stock Track | Clarity Pharmaceuticals Soars 5.15% Intraday on Commercial Manufacturing Deal for Cu-64 SAR-bisPSMA

BRIEF-Clarity Pharmaceuticals Signs Commercial Manufacturing Agreement

Clarity Pharmaceuticals Enters Manufacturing Deal With Nucleus Radiopharma for Diagnostic Imaging Agent

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/CU6.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CU6.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CU6.AU\",,,,,undefined,":{"symbol":"CU6.AU","market":"AU","secType":"STK","nameCN":"CLARITY PHARMACEUTICALS LTD","latestPrice":2.48,"timestamp":1787292720000,"preClose":2.62,"halted":0,"volume":2460943,"delay":0,"changeRate":-0.05343511450381684,"nameEN":"CLARITY PHARMACEUTICALS LTD","floatShares":274264090,"shares":372030071,"eps":-0.282253,"marketStatus":"Market Closed","change":-0.14,"latestTime":"08-21 16:12:00 AEST","open":2.58,"high":2.6,"low":2.44,"amount":6112772,"amplitude":0.061069,"askPrice":2.5,"askSize":3000,"bidPrice":2.47,"bidSize":5000,"shortable":3,"etf":0,"ttmEps":-0.282253,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787529600000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":2.62,"openAndCloseTimeList":[[1787270400000,1787292000000]],"volumeRatio":1.434727314908569,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CU6.AU","preClose":2.62,"auctionPrice":2.48,"auctionVolume":86670,"auction":3,"marketStatus":"盘后竞价","timestamp":1787292600774}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CU6.AU\",,,,,undefined,":{"symbol":"CU6.AU","floatShares":274264090,"roa":"-30.54%","roe":"-53.45%","lyrEps":-0.201427,"volumeRatio":1.434727314908569,"shares":372030071,"dividePrice":0,"high":2.6,"amplitude":0.061069,"preClose":2.62,"low":2.44,"week52Low":1.8,"pbRate":"3.96","psRate":"87.21","week52High":5.87,"institutionHeld":0,"latestPrice":2.48,"committee":0.25,"eps":-0.282253,"divideRate":0,"volume":2460943,"delay":0,"ttmEps":-0.282253,"open":2.58,"prevYearClose":3.38,"prevWeekClose":2.63,"prevMonthClose":2.37,"prevQuarterClose":2.14,"fiveDayClose":2.63,"twentyDayClose":2.35,"sixtyDayClose":2.43,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CU6.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CU6.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CU6.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657679547","title":"Clarity Pharmaceuticals - Reports Two Additional Complete Responses in Secure Trial at 8 Gbq Dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2657679547","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657679547?lang=en_us&edition=fundamental","pubTime":"2026-08-05 21:05","pubTimestamp":1785935112,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nFWN4421K3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","CU6.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657547678","title":"Clarity Pharmaceuticals - 74% Achieve Psa25, 63% Psa50, 53% Psa75, 26% Psa90 in Secure Trial at 8 Gbq","url":"https://stock-news.laohu8.com/highlight/detail?id=2657547678","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657547678?lang=en_us&edition=fundamental","pubTime":"2026-08-05 21:05","pubTimestamp":1785935112,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nFWN4421K3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","CU6.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657547674","title":"Clarity Pharmaceuticals - Most Adverse Events at 8 Gbq Dose were Mild or Moderate and Transient","url":"https://stock-news.laohu8.com/highlight/detail?id=2657547674","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657547674?lang=en_us&edition=fundamental","pubTime":"2026-08-05 21:05","pubTimestamp":1785935112,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nFWN4421K3:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CU6.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657547673","title":"Clarity Pharmaceuticals - 81% Achieve Disease Control, 31% Complete Response/Undetectable Disease at 8 Gbq Dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2657547673","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657547673?lang=en_us&edition=fundamental","pubTime":"2026-08-05 21:05","pubTimestamp":1785935112,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nFWN4421K3:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CU6.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657695547","title":"Clarity Pharmaceuticals Reports Two Additional Complete Responses in SECuRE Trial 8 GBq 67Cu-SAR-bisPSMA Cohort","url":"https://stock-news.laohu8.com/highlight/detail?id=2657695547","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657695547?lang=en_us&edition=fundamental","pubTime":"2026-08-05 21:04","pubTimestamp":1785935059,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals reports two additional complete responses in SECuRE trial 8 GBq 67Cu-SAR-bisPSMA cohortClarity Pharmaceuticals released a SECuRE trial update on Aug. 5, 2026, covering an inter","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDLbkLfrn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CU6.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657596646","title":"Clarity Pharmaceuticals Says Two New Participants in Prostate Cancer Trial Achieve Complete Response; Shares Jump 14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657596646","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657596646?lang=en_us&edition=fundamental","pubTime":"2026-08-05 09:11","pubTimestamp":1785892303,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals (ASX:CU6) said two new participants, evaluable at data cut-off in the group expansion phase of the phase I/IIa SECuRE trial in patients with prostate-specific membrane antigen-","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","CU6.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656078309","title":"ASX Penny Stocks Spotlight Clarity Pharmaceuticals And 2 More Compelling Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2656078309","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656078309?lang=en_us&edition=fundamental","pubTime":"2026-08-04 03:02","pubTimestamp":1785783739,"startTime":"0","endTime":"0","summary":"With Australia's reporting season in full swing, the ASX 200 is experiencing some early bearish sentiment, possibly influenced by global geopolitical tensions. Despite this cautious market atmosphere, penny stocks continue to capture attention for their potential value. Although the term \"penny stocks\" may seem outdated, these smaller or newer companies often hold promising opportunities for growth at lower price points. By focusing on those with strong financial fundamentals and clear growth...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-pnv/polynovo-shares/news/asx-penny-stocks-spotlight-clarity-pharmaceuticals-and-2-mor-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-pnv/polynovo-shares/news/asx-penny-stocks-spotlight-clarity-pharmaceuticals-and-2-mor-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CU6.AU","BK7096","BK7126","WGN.AU","BK7044","BK7508","PNV.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655339495","title":"Clarity Plans Phase Three Registrational Study of Neuroendocrine Tumor Treatment Candidate; Shares Jump 12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655339495","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655339495?lang=en_us&edition=fundamental","pubTime":"2026-07-31 12:25","pubTimestamp":1785471933,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals  plans to conduct a registrational phase three trial of the copper-64-SARTATE treatment candidate in neuroendocrine tumors, following an end of phase meeting with the US Food and Drug Administration, according to a Friday Australian bourse filing.Trial recruitment remains ongoing in the firm's Clarify phase three registrational trial for copper-64-SAR-bisPSMA as a diagnostic agent in patients with prostate cancer prior to undergoing radical prostatectomy. It is a non-randomized, open-label clinical trial in around 383 participants.The company held a cash position of AU$178.3 million as of June 30, per the filing. It said it holds over 60% of cash reserves in US dollars, adding that the recent appreciation of the Australian dollar resulted in an unrealized exchange loss of AU$5.9 million as of June 30.Clarity Pharmaceuticals' shares jumped nearly 12% in recent trading on Friday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","CU6.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651491008","title":"Clarity Pharmaceuticals Ltd-allison Rossiter Joins Clarity Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2651491008","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651491008?lang=en_us&edition=fundamental","pubTime":"2026-07-16 07:33","pubTimestamp":1784158380,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nTUE6GQ1NT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","CU6.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101267670","title":"Stock Track | Clarity Pharmaceuticals Soars 5.00% Intraday on R&D Tax Refund and New Manufacturing Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=1101267670","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101267670?lang=en_us&edition=fundamental","pubTime":"2026-07-15 13:06","pubTimestamp":1784091989,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals Ltd (ASX:CU6) saw its stock price surge 5.00% during intraday trading on Wednesday, as investors reacted to positive developments strengthening the company's financial...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CU6.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649930328","title":"Is Clarity Pharmaceuticals’ (ASX:CU6) Copper Theranostics Pipeline Redefining Its Long-Term Oncology Strategy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2649930328","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649930328?lang=en_us&edition=fundamental","pubTime":"2026-07-08 03:36","pubTimestamp":1783453008,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company, recently drew increased attention as its copper-based theranostic programs in cancer imaging and therapy progressed through multiple clinical trials.\nThe company’s proprietary Targeted Copper Theranostics platform, spanning indications from prostate cancer to paediatric oncology, has become a focal point for investors watching upcoming clinical and regulatory milestones.\nWith this backdrop, we’ll examine how excitement...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cu6/clarity-pharmaceuticals-shares/news/is-clarity-pharmaceuticals-asxcu6-copper-theranostics-pipeli","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cu6/clarity-pharmaceuticals-shares/news/is-clarity-pharmaceuticals-asxcu6-copper-theranostics-pipeli","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["VTHR","BK4585","SETM","BK4535","DBB","CHAT","PICK","BK4588","BK7096","QTOC","CU6.AU","AIPO","ARTY","AGIX","COPX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647304209","title":"ASX Growth Stocks With High Insider Ownership To Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2647304209","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647304209?lang=en_us&edition=fundamental","pubTime":"2026-06-30 03:08","pubTimestamp":1782760126,"startTime":"0","endTime":"0","summary":"As Australian traders anticipate a fresh start with the new financial year, geopolitical tensions in the Middle East continue to cast uncertainty over market stability, even as indices show signs of recovery. In such an environment, growth companies with high insider ownership can be particularly appealing, as they often indicate confidence from those who know the business best and may provide resilience against broader market volatility.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/9551736-choice1-main-header/1585186738088","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551736-choice1-main-header/1585186738088"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/diversified-financials/asx-hmc/hmc-capital-shares/news/asx-growth-stocks-with-high-insider-ownership-to-watch-10","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/diversified-financials/asx-hmc/hmc-capital-shares/news/asx-growth-stocks-with-high-insider-ownership-to-watch-10","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SKS.AU","GIVE.AU","CU6.AU","IISV.AU","BK7016","TOR.AU","ZYAU.AU","AR1.AU","BK7104","BK7116","SPL.AU","VAP.AU","BK7508","BK7017","FRS.AU","BK7162","BK7110","AEM.AU","BK7005","EIGA.AU","XJO.AU","GEAR.AU","XKO.AU","BK7062","BK7023","BK7501","VAS.AU","PNI.AU","BK7095","XAO.AU","STW.AU","IOZ.AU","DACE.AU","OZR.AU","SMI.AU","BK7096","IMLC.AU","AV1.AU","BBOZ.AU","IPX.AU","E200.AU","IIGF.AU","SLF.AU","OZF.AU","QRE.AU","QFN.AU","BEAR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643240283","title":"ASX Growth Companies With High Insider Ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2643240283","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643240283?lang=en_us&edition=fundamental","pubTime":"2026-06-15 03:08","pubTimestamp":1781464107,"startTime":"0","endTime":"0","summary":"As Australian shares experience a surge, buoyed by optimistic developments in international relations and robust performances on Wall Street, investors are keenly observing growth opportunities within the ASX. In this favorable market environment, companies with high insider ownership often attract attention as they can indicate strong confidence from those who know the business best.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-smi/santana-minerals-shares/news/asx-growth-companies-with-high-insider-ownership-14","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-smi/santana-minerals-shares/news/asx-growth-companies-with-high-insider-ownership-14","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7055","BK7508","EIQ.AU","TOR.AU","BK7017","BK7095","BK7110","BK7023","FRS.AU","AV1.AU","BK7096","AEM.AU","SMI.AU","SPL.AU","BK7016","BK7501","BK7062","CU6.AU","SKS.AU","AR1.AU","MAU.AU","BK7104","LYL.AU","PNI.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635566437","title":"ASX Growth Leaders With Insider Stakes May 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635566437","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635566437?lang=en_us&edition=fundamental","pubTime":"2026-05-14 03:10","pubTimestamp":1778699413,"startTime":"0","endTime":"0","summary":"As the Australian share market navigates a post-Budget environment marked by cautious spending and external pressures from U.S. inflation concerns, investors are keenly observing how these factors influence local indices. In such a climate, growth companies with high insider ownership may offer unique insights into potential resilience and alignment of interests between management and shareholders, making them noteworthy for those seeking stability amid broader market fluctuations.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/software/asx-eol/energy-one-shares/news/asx-growth-leaders-with-insider-stakes-may-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/software/asx-eol/energy-one-shares/news/asx-growth-leaders-with-insider-stakes-may-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7023","TOR.AU","BK7016","BK7096","BK7017","MAU.AU","BK7104","BK7095","BK7508","AR1.AU","EIQ.AU","CU6.AU","BK7501","PNI.AU","SKS.AU","EOL.AU","BK7091","BK7110","SPL.AU","AEM.AU","CUV.AU","AV1.AU","BK7062","BK7067","PNC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632986104","title":"ASX Growth Companies With Significant Insider Ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2632986104","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632986104?lang=en_us&edition=fundamental","pubTime":"2026-05-04 03:08","pubTimestamp":1777835284,"startTime":"0","endTime":"0","summary":"Amidst a challenging period for the Australian share market, marked by a potential seventh consecutive day of declines and significant economic pressures from global events, investors are increasingly seeking resilient opportunities. In such an environment, growth companies with high insider ownership can be particularly attractive as they often indicate strong alignment between management and shareholder interests, potentially providing stability and confidence during volatile times.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/3041000-choice1-main-header/1585186744280","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3041000-choice1-main-header/1585186744280"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/capital-goods/asx-dur/duratec-shares/news/asx-growth-companies-with-significant-insider-ownership","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/capital-goods/asx-dur/duratec-shares/news/asx-growth-companies-with-significant-insider-ownership","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7096","BK7110","BK7506","BK7104","BK7084","AV1.AU","BK7016","BK7508","BK7017","AEM.AU","CU6.AU","BK7095","TOR.AU","DUR.AU","EMR.AU","MAU.AU","SKS.AU","BK7055","TCG.AU","BK7501","EIQ.AU","BK7023","SPL.AU","AR1.AU","ELS.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631503028","title":"Clarity Pharmaceuticals to Start Registrational Phase 3 Trial in Neuroendocrine Tumors After US FDA Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2631503028","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631503028?lang=en_us&edition=fundamental","pubTime":"2026-04-30 12:43","pubTimestamp":1777524230,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals  will start a registrational phase 3 trial of copper-64-SARTATE in neuroendocrine tumors, following a successful end-of-phase meeting with the US Food and Drug Administration , according to a Thursday Australian bourse filing.The company plans to recruit around 70 participants for the trial.Clarity is also conducting recruitment for its registrational phase 3 positron emission tomography imaging trial of participants with high-risk prostate cancer prior to radical prostatectomy using copper-64-SAR-bisPSMA in the US and Australia, per the filing. It plans to recruit around 383 participants.The trial will assess the diagnostic performance of copper-64-SAR-bisPSMA positron emission tomography in detecting prostate cancer within the pelvic lymph nodes, the filing said.Clarity Pharmaceuticals' shares fell nearly 2% in recent trading on Thursday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LABU","BK4588","BK4585","BK7096","CU6.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629586965","title":"Trade Alert: CEO, MD & Executive Director Of Clarity Pharmaceuticals Michelle Parker Has Sold Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2629586965","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629586965?lang=en_us&edition=fundamental","pubTime":"2026-04-24 04:38","pubTimestamp":1776976709,"startTime":"0","endTime":"0","summary":"We wouldn't blame Clarity Pharmaceuticals Ltd ( ASX:CU6 ) shareholders if they were a little worried about the fact...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cu6/clarity-pharmaceuticals-shares/news/trade-alert-ceo-md-executive-director-of-clarity-pharmaceuti","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cu6/clarity-pharmaceuticals-shares/news/trade-alert-ceo-md-executive-director-of-clarity-pharmaceuti","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7096","CU6.AU","BK4196","MD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184551801","title":"Stock Track | Clarity Pharmaceuticals Soars 5.15% Intraday on Commercial Manufacturing Deal for Cu-64 SAR-bisPSMA","url":"https://stock-news.laohu8.com/highlight/detail?id=1184551801","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184551801?lang=en_us&edition=fundamental","pubTime":"2026-04-15 08:06","pubTimestamp":1776211595,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals Ltd (CU6.AU) saw its stock price soar 5.15% during intraday trading on Wednesday, following the announcement of a significant commercial manufacturing agreement. The company...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CU6.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627460109","title":"BRIEF-Clarity Pharmaceuticals Signs Commercial Manufacturing Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2627460109","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627460109?lang=en_us&edition=fundamental","pubTime":"2026-04-14 09:21","pubTimestamp":1776129702,"startTime":"0","endTime":"0","summary":"BRIEF-Clarity Pharmaceuticals Signs Commercial Manufacturing AgreementApril 14 (Reuters) - Clarity Pharmaceuticals Ltd CU6.AX:SIGNS COMMERCIAL MANUFACTURING AGREEMENTCOMMERCIAL MANUFACTURING AGREEMENT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nFWN40W0IV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","CU6.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627461075","title":"Clarity Pharmaceuticals Enters Manufacturing Deal With Nucleus Radiopharma for Diagnostic Imaging Agent","url":"https://stock-news.laohu8.com/highlight/detail?id=2627461075","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627461075?lang=en_us&edition=fundamental","pubTime":"2026-04-14 07:27","pubTimestamp":1776122846,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals  signed a commercial manufacturing agreement for its Cu-64 SAR-bisPSMA next-generation diagnostic imaging agent with Nucleus Radiopharma, according to a Tuesday filing with the Australian bourse.The agreement includes manufacturing at Nucleus Radiopharma's facility in Rochester, Minnesota, which has a production capacity of around 50,000 patient doses per year, as well as future production at a Spring House, Pennsylvania, facility planned to open in 2028 with a capacity of up to 600,000 doses per year.The two facilities will service key commercial markets, with distribution to all 50 US states and some international locations including Europe, per the filing.Clarity Pharmaceuticals plans to commercially launch the new diagnostic imaging agent after completing phase 3 registrational trials and obtaining new drug application approval from the US Food and Drug Administration.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","CU6.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":48,"code":"91000000","status":"200"}]}}